Joachim Vilstrup
YOU?
Author Swipe
View article: A Novel TREM2 Small Molecule Agonist MTX46943 Re‐Programs Human Microglia and Reduces Amyloid Pathology <i>In Vivo</i>
A Novel TREM2 Small Molecule Agonist MTX46943 Re‐Programs Human Microglia and Reduces Amyloid Pathology <i>In Vivo</i> Open
Background Microglia function as brain‐resident innate immune cells that maintain brain health and play a critical role in resolving Alzheimer´s Disease (AD) pathology. TREM2 modulates microglia responses to neutralize misfolded proteins a…
View article: Reshaping the progranulin/sortilin interaction for targeted degradation of extracellular proteins
Reshaping the progranulin/sortilin interaction for targeted degradation of extracellular proteins Open
Targeted protein degradation (TPD) using PROteolysis TArgeting Chimeras (PROTACs) is a rapidly emerging therapeutic strategy for difficult-to-drug cytosolic proteins. PROTACs are heterobifunctional small molecules that bridge the target wi…
View article: Rare missense variants of the leukocyte common antigen related receptor (LAR) display reduced activity in transcellular adhesion and synapse formation
Rare missense variants of the leukocyte common antigen related receptor (LAR) display reduced activity in transcellular adhesion and synapse formation Open
The leukocyte common antigen related receptor (LAR) is a member of the LAR receptor protein tyrosine phosphatase (RPTP) family of synaptic adhesion molecules that contribute to the proper alignment and specialization of synaptic connection…
View article: Targeting PCSK9 to tackle cardiovascular disease
Targeting PCSK9 to tackle cardiovascular disease Open
Lowering blood cholesterol levels efficiently reduces the risk of developing atherosclerotic cardiovascular disease (ASCVD), including coronary artery disease (CAD), which is the main cause of death worldwide. CAD is caused by plaque forma…
View article: PCSK9 deficiency alters brain lipid composition without affecting brain development and function
PCSK9 deficiency alters brain lipid composition without affecting brain development and function Open
PCSK9 induces lysosomal degradation of the low-density lipoprotein (LDL) receptor (LDLR) in the liver, hereby preventing removal of LDL cholesterol from the circulation. Accordingly, PCSK9 inhibitory antibodies and siRNA potently reduce LD…
View article: Heparan sulfate proteoglycans present PCSK9 to the LDL receptor
Heparan sulfate proteoglycans present PCSK9 to the LDL receptor Open
Coronary artery disease is the main cause of death worldwide and accelerated by increased plasma levels of cholesterol-rich low-density lipoprotein particles (LDL). Circulating PCSK9 contributes to coronary artery disease by inducing lysos…